{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:00:42Z","timestamp":1794261642604,"version":"4.9.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002947","name":"Anhui Medical University","doi-asserted-by":"publisher","award":["LCYJ2021YB005"],"award-info":[{"award-number":["LCYJ2021YB005"]}],"id":[{"id":"10.13039\/501100002947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.heliyon.2024.e35757","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T23:05:58Z","timestamp":1722639958000},"page":"e35757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Ceftazidime-avibactam: Combination therapy versus monotherapy in the challenge of pneumonia caused by carbapenem-resistant Klebsiella pneumoniae"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7722-7153","authenticated-orcid":false,"given":"Chang-wei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9782-8802","authenticated-orcid":false,"given":"Li-fen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 7","key":"10.1016\/j.heliyon.2024.e35757_bib1","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.1093\/cid\/ciz830","article-title":"Treatment options for carbapenem-resistant gram-negative bacterial infections","volume":"69","author":"Doi","year":"2019","journal-title":"Clin. Infect. Dis. : an official publication of the Infectious Diseases Society of America"},{"key":"10.1016\/j.heliyon.2024.e35757_bib2","article-title":"Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications","volume":"352","author":"Iredell","year":"2016","journal-title":"Br. Med. J."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e35757_bib3","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1473-3099(09)70054-4","article-title":"The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria","volume":"9","author":"Nordmann","year":"2009","journal-title":"Lancet Infect. Dis."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e35757_bib4","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40121-021-00479-7","article-title":"Ceftazidime-avibactam in combination with in vitro non-susceptible antimicrobials versus ceftazidime-avibactam in monotherapy in critically ill patients with carbapenem-resistant Klebsiella pneumoniae infection: a retrospective cohort study","volume":"10","author":"Zheng","year":"2021","journal-title":"Infect. Dis. Ther."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e35757_bib5","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1093\/cid\/civ723","article-title":"Optimal usage of colistin: are we any closer?","volume":"61","author":"Pogue","year":"2015","journal-title":"Clin. Infect. Dis. : an official publication of the Infectious Diseases Society of America"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e35757_bib6","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1128\/JCM.01399-15","article-title":"Outbreak of colistin-resistant, carbapenemase-producing Klebsiella pneumoniae: are we at the end of the road?","volume":"53","author":"van Duin","year":"2015","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.heliyon.2024.e35757_bib7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2147\/IDR.S349004","article-title":"Ceftazidime-avibactam versus colistin for the treatment of infections due to carbapenem-resistant enterobacterales: a multicenter cohort study","volume":"15","author":"Almangour","year":"2022","journal-title":"Infect. Drug Resist."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e35757_bib8","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1128\/AAC.00220-16","article-title":"In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime-avibactam (INFORM 2012 to 2014)","volume":"60","author":"Nichols","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e35757_bib9","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ijantimicag.2014.12.033","article-title":"In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates","volume":"45","author":"Testa","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e35757_bib10","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ijantimicag.2019.08.025","article-title":"Efficacy of ceftazidime\/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: a meta-analysis","volume":"54","author":"Onorato","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e35757_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics9070388","article-title":"Ceftazidime-avibactam combination therapy compared to ceftazidime-avibactam monotherapy for the treatment of severe infections due to carbapenem-resistant pathogens: a systematic review and network meta-analysis","volume":"9","author":"Fiore","year":"2020","journal-title":"Antibiotics"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e35757_bib12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/cid\/ciac268","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e35757_bib13","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e35757_bib14","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"Apache II: a severity of disease classification system","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit. Care Med."},{"issue":"suppl_2","key":"10.1016\/j.heliyon.2024.e35757_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciy657","article-title":"Current status and trends of antibacterial resistance in China","volume":"67","author":"Hu","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e35757_bib16","series-title":"Performance Standards for Antimicrobial Susceptibility Testing","year":"2021"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e35757_bib17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.diagmicrobio.2010.12.002","article-title":"Multiplex PCR for detection of acquired carbapenemase genes","volume":"70","author":"Poirel","year":"2011","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e35757_bib18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jgar.2018.07.010","article-title":"Evaluation of ceftazidime\/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa","volume":"15","author":"Rodr\u00edguez-N\u00fa\u00f1ez","year":"2018","journal-title":"Journal of global antimicrobial resistance"},{"key":"10.1016\/j.heliyon.2024.e35757_bib19","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3389\/fphar.2020.00786","article-title":"Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy","volume":"11","author":"Li","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e35757_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e35757_bib21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin. Infect. Dis. : an official publication of the Infectious Diseases Society of America"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e35757_bib22","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jceh.2022.04.016","article-title":"Ceftazidime-avibactam for the treatment of carbapenem-resistant Klebsiella pneumoniae infections in patients with liver cirrhosis","volume":"12","author":"Feldman","year":"2022","journal-title":"J Clin Exp Hepatol"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e35757_bib23","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/cid\/ciab176","article-title":"Ceftazidime-avibactam use for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae infections: a retrospective observational multicenter study","volume":"73","author":"Tumbarello","year":"2021","journal-title":"Clin. Infect. Dis. : an official publication of the Infectious Diseases Society of America"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e35757_bib24","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/cid\/ciy576","article-title":"Ceftazidime\/avibactam, meropenem\/vaborbactam, or both? Clinical and formulary considerations","volume":"68","author":"Pogue","year":"2019","journal-title":"Clin. Infect. Dis. : an official publication of the Infectious Diseases Society of America"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e35757_bib25","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/jac\/dkx419","article-title":"In vitro and in vivo activity of single and dual antimicrobial agents against KPC-producing Klebsiella pneumoniae","volume":"73","author":"Nath","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e35757_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00779-19","article-title":"Evaluation of the synergy of ceftazidime-avibactam in combination with meropenem, amikacin, aztreonam, colistin, or fosfomycin against well-characterized multidrug-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa","volume":"63","author":"Mikhail","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.heliyon.2024.e35757_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijid.2017.09.017","article-title":"In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates","volume":"65","author":"Gaibani","year":"2017","journal-title":"Int. J. Infect. Dis."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e35757_bib28","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1089\/mdr.2018.0234","article-title":"Activity of ceftazidime-avibactam alone and in combination with ertapenem, fosfomycin, and tigecycline against carbapenemase-producing Klebsiella pneumoniae","volume":"25","author":"Ojdana","year":"2019","journal-title":"Microb. Drug Resist."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e35757_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0258426","article-title":"Evaluation of ceftazidime\/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae by in vitro time-kill experiment","volume":"16","author":"Wang","year":"2021","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e35757_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02313-19","article-title":"Meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant enterobacteriaceae infections","volume":"64","author":"Ackley","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e35757_bib31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13054-020-2742-9","article-title":"Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae","volume":"24","author":"Falcone","year":"2020","journal-title":"Crit. Care"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e35757_bib32","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz522","article-title":"Real-world experience with ceftazidime-avibactam for multidrug-resistant gram-negative bacterial infections","volume":"6","author":"Jorgensen","year":"2019","journal-title":"Open Forum Infect. Dis."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e35757_bib33","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.1128\/AAC.01019-15","article-title":"Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance","volume":"59","author":"Pitout","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e35757_bib34","first-page":"562","article-title":"A five-year surveillance of carbapenemase-producing Klebsiella pneumoniae in a pediatric hospital in China reveals increased predominance of NDM-1","volume":"30","author":"Dong","year":"2017","journal-title":"Biomed. Environ. Sci."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e35757_bib35","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1128\/CMR.00117-13","article-title":"OXA \u03b2-lactamases","volume":"27","author":"Evans","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.heliyon.2024.e35757_bib36","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fcimb.2020.00314","article-title":"Dissemination of carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) among carbapenem-resistant enterobacteriaceae isolated from adult and children patients in China","volume":"10","author":"Han","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.heliyon.2024.e35757_bib37","doi-asserted-by":"crossref","first-page":"7107","DOI":"10.2147\/IDR.S385240","article-title":"In vitro and in vivo antimicrobial activities of ceftazidime\/avibactam alone or in combination with aztreonam against carbapenem-resistant enterobacterales","volume":"15","author":"Lu","year":"2022","journal-title":"Infect. Drug Resist."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024117884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024117884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T22:39:15Z","timestamp":1773182355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024117884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":37,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2405844024117884"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e35757","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ceftazidime-avibactam: Combination therapy versus monotherapy in the challenge of pneumonia caused by carbapenem-resistant Klebsiella pneumoniae","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e35757","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e35757"}}